Analysts Issue FY2024 Earnings Forecasts for Precision BioSciences, Inc. (NASDAQ:DTIL)

Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Investment analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Precision BioSciences in a research report issued on Thursday, August 22nd. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $2.03 for the year, up from their prior estimate of ($2.99). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Precision BioSciences’ FY2026 earnings at $0.06 EPS, FY2027 earnings at $0.19 EPS and FY2028 earnings at $0.38 EPS.

Precision BioSciences (NASDAQ:DTIL – Get Your Free Report ) last released its quarterly earnings results on Thursday, August 1st. The company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $4.23. The company had revenue of $49.90 million for the quarter, compared to analysts’ expectations of $8.50 million. Precision BioSciences had a net margin of 19.36% and a negative return on equity of 10.76%. During the same period last year, the company earned ($3.00) EPS.

Separately, Guggenheim initiated coverage on Precision BioSciences in a report on Tuesday, April 30th. They set a “buy” rating and a $19.00 price objective on the stock.

See the latest stock analysis on DTIL

Precision BioSciences Stock Performance

Shares of DTIL stock opened at $9.69 on Monday. The company’s 50-day simple moving average is $9.54 and its 200-day simple moving average is $11.36. The company has a market cap of $67.11 million, a price-to-earnings ratio of -1.30 and a beta of 1.74. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $19.43.

Institutional investors weigh in on Precision BioSciences

An institutional investor recently bought a new position in shares of Precision BioSciences. Janus Henderson Group PLC acquired a new stake in Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned approximately 8.29% of Precision BioSciences as of its most recent SEC filing. 37.99% of shares are owned by institutional investors and hedge funds.

About Precision BioSciences

(Get a free report)

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene modifications, including gene deletion, insertion and excision in the United States. The company offers ARCUS, a genome editing platform for inserting, deleting and repairing DNA genomes. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with cuts and direct modifications, as well as to inactivate integrated HBV DNA for long-term antigen reduction hepatitis B surface; PBGENE-PMM for the treatment of m.3243-associated primary mitochondrial myopathy (PMM) that is expected to have an IND and/or CTA.

Featured stories

Get news and reviews for Precision BioSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Precision BioSciences and related companies with MarketBeat.com’s FREE daily email newsletter.